- Most patients with PSS reported symptoms persisting or worsening despite care; only 13% reported improvement.
- Barriers in access, affordability and clinician communication were linked to higher odds of symptom persistence and deterioration across countries.
- Longer untreated duration varied by country; early access alone may not suffice, and insurance dissatisfaction worsened outcomes notably in Germany.
BMJ Public Health. 2026 Aug 4;4(3):e004470. doi: 10.1136/bmjph-2025-004470. eCollection 2026.
ABSTRACT
INTRODUCTION: Persistent somatic symptoms (PSS) are prevalent across Europe. As little is known about affected patients’ healthcare experience and its relationship with symptom outcomes, these were explored in a cross-sectional survey across four European countries.
METHODS: This cross-sectional online survey was distributed in Germany, Italy, the Netherlands and Poland (04/2023-05/2024). The survey included adults aged ≥18 years with PSS (Patient Health Questionnaire-15 ≥10) who had used healthcare services in the past year. Healthcare factors were assessed across four dimensions: availability, affordability, accessibility and adequacy. Multinomial logistic regression examined associations between healthcare factors and symptom course (improvement, persistence and deterioration). Duration of untreated illness was also compared across countries.
RESULTS: Of 595 participants (87% female) included in regression analyses, 13% reported improvement, 70% persistence and 17% deterioration. Duration of untreated illness was longest in Poland, followed by Italy, the Netherlands and Germany (48, 24, 12 and 3 months, respectively, p<0.001). After adjusting for age, gender and country, nearly all healthcare factors were associated with higher odds of symptom persistence and deterioration across countries, including difficulty accessing services (persistence OR 1.39 (95% CI 1.12 to 1.75); deterioration OR 1.84 (95% CI 1.39 to 2.44)), financial difficulties (persistence OR 1.60 (95% CI 1.25 to 2.05); deterioration OR 2.17 (95% CI 1.59 to 2.96)), postponing care due to costs (persistence OR 1.54 (95% CI 1.07 to 2.19); deterioration OR 2.53 (95% CI 1.67 to 3.86)), dissatisfaction with insurance (persistence OR 1.26 (95% CI 1.03 to 1.54); deterioration OR 1.57 (95% CI 1.19 to 2.06)) and poor clinician-patient communication (persistence OR 1.19 (95% CI 1.11 to 1.26); deterioration OR 1.25 (95% CI 1.16 to 1.34)). Country-specific effects were found only for insurance satisfaction, with dissatisfaction linked to worse outcomes in Germany (persistence OR 1.87 (95% CI 1.19 to 2.93); deterioration OR 4.02 (95% CI 2.09 to 7.74)).
CONCLUSIONS: Across four European countries, patients with PSS reported that their symptoms did not improve despite receiving care. This was the case even in countries with substantially shorter treatment delays, suggesting that early access alone may not be sufficient. Barriers related to access, affordability and communication were associated with worse outcomes, highlighting key areas for improvement across healthcare systems.
PMID:42568934 | PMC:PMC13448617 | DOI:10.1136/bmjph-2025-004470
Share Evidence Blueprint
Save to Google Notes
Search Google Scholar
Save as PDF
⭐ My Revision List
